<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Mucopolysaccharidoses: Treatment
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Mucopolysaccharidoses: Treatment
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Mucopolysaccharidoses: Treatment
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sihoun Hahn, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Marc C Patterson, MD, FRACP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Elizabeth TePas, MD, MS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 06, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H944973654">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The mucopolysaccharidoses (MPS) are lysosomal storage disorders caused by the deficiency of enzymes required for the stepwise breakdown of glycosaminoglycans (GAGs), also known as mucopolysaccharides. These conditions are differentiated by their clinical features and age of presentation (
         <a class="graphic graphic_table graphicRef57733" href="/z/d/graphic/57733.html" rel="external">
          table 1
         </a>
         ). The MPS can affect many different systems, including the respiratory, cardiovascular, skeletal, and neurologic systems. Enzyme replacement therapy (ERT) is available for some MPS. Other therapies focus on treatment of symptoms.
        </p>
        <p>
         Treatment of the MPS is reviewed here. The clinical features and diagnosis of these disorders, as well as associated complications, are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2931.html" rel="external">
          "Mucopolysaccharidoses: Clinical features and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2932.html" rel="external">
          "Mucopolysaccharidoses: Complications"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H447978766">
         <span class="h1">
          OVERVIEW OF MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most therapies for MPS are directed toward treatment of complications and are not specific for the underlying abnormality. Supportive or symptomatic management can improve the quality of life for patients and their families, but they cannot prevent the inevitable decline in function. However, specific therapies, such as enzyme replacement therapy (ERT), hematopoietic cell transplantation (HCT), and gene therapy, alone or in combination, may alter the natural history of these disorders [
         <a href="#rid1">
          1
         </a>
         ]. The choice of therapy depends upon the type of MPS and the disease severity in the specific patient. Management of complications is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/2932.html" rel="external">
          "Mucopolysaccharidoses: Complications"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1496607896">
         <span class="h1">
          ENZYME REPLACEMENT THERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Enzyme replacement therapy (ERT) is approved in the United States, European Union, and several other countries for patients with MPS I, MPS II, MPS IVA, MPS VI, and MPS VII (
         <a class="graphic graphic_table graphicRef57733" href="/z/d/graphic/57733.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid2">
          2
         </a>
         ]. Indications vary across the MPS, but generally ERT is used in patients with moderate-to-severe disease or clinical complications. The exception is patients &lt;2 years of age with severe MPS I (Hurler), for whom hematopoietic cell transplantation (HCT) is preferred if there is a suitable donor. (See
         <a class="local">
          'Hematopoietic cell transplantation'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3977465703">
         <span class="h2">
          MPS I
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with MPS I (Hurler, Hurler-Scheie, and Scheie syndromes), treatment with recombinant human alpha-L-iduronidase (
         <a class="drug drug_pediatric" data-topicid="13320" href="/z/d/drug information/13320.html" rel="external">
          laronidase
         </a>
         ), the deficient enzyme, reduces lysosomal storage in the liver and improves some clinical manifestations while stabilizing others [
         <a href="#rid3">
          3-7
         </a>
         ]. Better outcome is achieved if laronidase is initiated before serious complications occur [
         <a href="#rid6">
          6,8
         </a>
         ]. The recommended dose is 0.58 mg/kg (rounded up to the nearest whole vial) given intravenously (IV) once a week.
        </p>
        <p>
         <a class="drug drug_pediatric" data-topicid="13320" href="/z/d/drug information/13320.html" rel="external">
          Laronidase
         </a>
         is approved in the United States for patients with Hurler and Hurler-Scheie forms of MPS I and for patients with the Scheie form who have moderate-to-severe symptoms. In the European Union, it is indicated to treat the nonneurologic aspects of confirmed MPS I [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
         The approval of
         <a class="drug drug_pediatric" data-topicid="13320" href="/z/d/drug information/13320.html" rel="external">
          laronidase
         </a>
         was based upon a phase-III study in 45 patients with MPS I [
         <a href="#rid4">
          4
         </a>
         ]. In this trial, patients were randomly assigned to weekly IV infusions of laronidase or placebo [
         <a href="#rid4">
          4
         </a>
         ]. After 26 weeks of therapy, patients in the laronidase group compared with those in the placebo group had improved forced vital capacity (FVC) and walking distance and reduced hepatomegaly and urinary glycosaminoglycan (GAG) levels. In addition, laronidase improved sleep apnea and shoulder flexion among the more severely affected patients.
        </p>
        <p>
         All 45 patients were enrolled in a 3.5-year open-label extension study, which 40 completed [
         <a href="#rid9">
          9
         </a>
         ]. As in earlier trials, urinary GAG levels decreased within the first 12 weeks and liver volume within the first year. Stabilization or improvement was also noted in percent predicted FVC, six-minute walk test, sleep apnea, shoulder flexion, and activities of daily living. Corneal clouding did not change appreciably. Infusion reactions were generally mild and decreased after six months. Although 93 percent of patients developed antibodies to
         <a class="drug drug_pediatric" data-topicid="13320" href="/z/d/drug information/13320.html" rel="external">
          laronidase
         </a>
         , 29 percent were seronegative at their last assessment.
        </p>
        <p>
         Similar findings (including normalized liver size, further increased range of motion, increased height and weight growth, and improved airway size) were noted in a series of 10 patients at one year and in 5 of those patients at six years of follow-up [
         <a href="#rid3">
          3,5,10
         </a>
         ]. The five patients had some worsening of pre-existing neurologic symptoms, and carpal tunnel syndrome still required release. Patients with substantial valvular disease at baseline continued to progress, needing valve replacement, but those with mild or minimal disease may have stabilized. At the six-year follow-up, 4 of the original 10 patients had died of various causes, including two with postsurgical complications for pre-existing problems.
        </p>
        <p>
         The safety and efficacy of
         <a class="drug drug_pediatric" data-topicid="13320" href="/z/d/drug information/13320.html" rel="external">
          laronidase
         </a>
         in children younger than five years were illustrated in a prospective, open-label, multinational study that included 16 children with Hurler syndrome and four with Hurler-Scheie [
         <a href="#rid11">
          11
         </a>
         ]. Clinical improvements were noted in 94 percent of patients at week 52 (eg, improved hepatomegaly, left ventricular hypertrophy, apnea/hypopnea index). The mean urine GAG level declined by approximately 50 percent by 13 weeks and was sustained thereafter.
        </p>
        <p>
         ERT in patients with MPS I does not appear to reverse corneal or optic disc changes [
         <a href="#rid5">
          5,12
         </a>
         ]. Intrathecal ERT in a canine model of Hurler syndrome normalized GAG storage in the brain and decreased spinal meningeal storage [
         <a href="#rid13">
          13
         </a>
         ]. One patient with MPS I (Hurler syndrome) and progressive cognitive decline demonstrated improved neurocognitive performance after intrathecal ERT [
         <a href="#rid14">
          14
         </a>
         ]. Another patient with MPS I and spinal cord compression was treated with four monthly intrathecal infusions of ERT and was shown to have improvement in pulmonary function and the 12-minute walk test [
         <a href="#rid15">
          15
         </a>
         ]. Intrathecal therapy remains experimental.
        </p>
        <p class="headingAnchor" id="H3462511717">
         <span class="h2">
          MPS II
         </span>
         <span class="headingEndMark">
          —
         </span>
         ERT for MPS II (Hunter syndrome) with recombinant human iduronate sulfatase (
         <a class="drug drug_pediatric" data-topicid="100321" href="/z/d/drug information/100321.html" rel="external">
          idursulfase
         </a>
         ) is licensed for use in many countries worldwide [
         <a href="#rid16">
          16-18
         </a>
         ]. Idursulfase (0.5 mg/kg) is administered in weekly infusions [
         <a href="#rid16">
          16,19
         </a>
         ]. ERT is not predicted to cross the blood-brain barrier. Improvements in physical and respiratory function and reduction in mortality have been reported [
         <a href="#rid20">
          20
         </a>
         ]. Somatic improvements may occur even in the most severe patients, but cognitive benefits have not been seen [
         <a href="#rid21">
          21
         </a>
         ]. Thus, ERT is typically started in newly identified patients with MPS II but not those with end-stage brain disease.
        </p>
        <p>
         In one clinical trial, 96 male patients (ages 5 to 31 years) treated with weekly infusions of
         <a class="drug drug_pediatric" data-topicid="100321" href="/z/d/drug information/100321.html" rel="external">
          idursulfase
         </a>
         for 53 weeks had a mean increase in the six-minute walk test and percent predicted FVC [
         <a href="#rid18">
          18,22
         </a>
         ]. Treatment also decreased mean urinary GAG levels and liver and spleen volume. Growth, sleep apnea, cardiac function, quality of life, and mortality were not examined. Anaphylactoid reactions were observed in some patients during infusion. The most common infusion-related reactions included headache, fever, cutaneous reaction, and hypertension. The frequency of infusion-related reactions decreased with time.
        </p>
        <p>
         A retrospective review of 22 patients (aged 18 months to 21 years) treated with ERT for at least two consecutive years examined improvement in somatic manifestations (skeletal disease, joint range of motion, liver/spleen size, respiratory infections, cardiac disease, diarrhea, skin/hair texture, and disease-related hospitalizations) [
         <a href="#rid23">
          23
         </a>
         ]. All patients had improvement in four or more somatic signs/symptoms, with the majority showing improvement in five to six of these findings. Limited experience in children younger than five years of age suggests that early initiation of ERT may delay or prevent the development of irreversible manifestations of the disease [
         <a href="#rid24">
          24,25
         </a>
         ]. A phase-III clinical trial of intrathecal administration of
         <a class="drug drug_pediatric" data-topicid="100321" href="/z/d/drug information/100321.html" rel="external">
          idursulfase
         </a>
         is ongoing.
        </p>
        <p>
         A clinical trial is underway to test the safety and determine a well-tolerated dose of an investigational ERT in adults with MPS II. This investigational treatment is designed to cross the blood-brain barrier, which existing approved treatments for MPS II are unable to do, and as such should treat both the body-related and central nervous system (CNS) related symptoms and complications of MPS II.
        </p>
        <p class="headingAnchor" id="H460694076">
         <span class="h2">
          MPS III
         </span>
         <span class="headingEndMark">
          —
         </span>
         Intrathecal ERT for MPS IIIA was ineffective in clinical trials [
         <a href="#rid26">
          26
         </a>
         ]. Early-phase trials for MPS IIIB using IV- or intracerebroventricular (ICV) delivered ERT are underway. Intrathecal therapy remains experimental.
        </p>
        <p class="headingAnchor" id="H1031152336">
         <span class="h2">
          MPS IVA
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_pediatric" data-topicid="97560" href="/z/d/drug information/97560.html" rel="external">
          Elosulfase alfa
         </a>
         (recombinant human N-acetylgalactosamine-6-sulfate sulfatase [rhGALNS]) is approved for the treatment of MPS IVA (Morquio A syndrome) [
         <a href="#rid27">
          27
         </a>
         ]. In a randomized trial of 176 patients with MPS IVA, patients who received weekly infusions of elosulfase alfa for 24 weeks walked 22.5 meters farther in six minutes, on average, than patients who received placebo [
         <a href="#rid28">
          28
         </a>
         ]. Urine keratan sulfate levels were also reduced. No further improvement in walking ability was seen in a 48-week extension trial. In premarketing clinical trials, 8 percent of patients had anaphylactic reactions during the infusions, prompting inclusion of a boxed warning for the drug. Premedication with an antihistamine, with or without an antipyretic, prior to infusion is recommended.
        </p>
        <p class="headingAnchor" id="H3923113981">
         <span class="h2">
          MPS VI
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_pediatric" data-topicid="16064" href="/z/d/drug information/16064.html" rel="external">
          Galsulfase
         </a>
         (recombinant human N-acetylgalactosamine-4-sulfatase [rhASB]) is approved as specific therapy for MPS VI (Maroteaux-Lamy syndrome) [
         <a href="#rid29">
          29
         </a>
         ]. Galsulfase (1 mg/kg/dose) is administered once weekly. ERT for MPS VI decreases urinary GAG excretion and improves patient function and survival.
        </p>
        <p>
         In preapproval randomized clinical trials, patients with severe manifestations of MPS VI who received weekly infusions of
         <a class="drug drug_pediatric" data-topicid="16064" href="/z/d/drug information/16064.html" rel="external">
          galsulfase
         </a>
         for 24 weeks had reduced urinary GAG excretion and improved functional status (outcomes included six-minute walk test, shoulder range of motion, and joint pain) [
         <a href="#rid30">
          30,31
         </a>
         ]. In an open-label, phase-II trial, patients who received weekly infusions for 48 weeks responded with improved endurance and decreased pain compared with their baseline [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
         In a phase-III trial, patients in the treatment group had greater mean increases in the distance walked in 12 minutes and the number of stairs climbed in 3 minutes than those in the placebo group (a difference between groups of 92 meters [95% CI 11-172] and 5.7 stairs per minute [95% CI -0.1-11.5], respectively) [
         <a href="#rid33">
          33,34
         </a>
         ]. Increased survival, in addition to improved pulmonary function and endurance, was demonstrated in a long-term study of
         <a class="drug drug_pediatric" data-topicid="16064" href="/z/d/drug information/16064.html" rel="external">
          galsulfase
         </a>
         treatment (mean duration of ERT was 6.8 years) [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p>
         Intrathecal ERT for MPS VI has been studied in a cat model [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2160263086">
         <span class="h2">
          MPS VII
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_pediatric" data-topicid="118276" href="/z/d/drug information/118276.html" rel="external">
          Vestronidase alfa
         </a>
         (recombinant human beta-glucuronidase [rhGUS]) is approved for the treatment of MPS VII [
         <a href="#rid37">
          37
         </a>
         ]. In a phase-III clinical trial, 23 patients aged 5 months to 25 years with MPS VII were treated with vestronidase alfa at doses up to 4 mg/kg every two week for up to 164 weeks. Patients showed improvement in the six-minute walk test at 24 weeks (mean difference 18 meters compared with placebo) and continued to demonstrate improvement after 120 weeks. Two patients also had marked improvement in pulmonary function. The effect on CNS manifestations was not determined. The recommended dose is 4 mg/kg given IV every other week.
        </p>
        <p class="headingAnchor" id="H1119956597">
         <span class="h1">
          HEMATOPOIETIC CELL TRANSPLANTATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hematopoietic cell transplantation (HCT) leads to the progressive replacement of enzyme-deficient hematopoietic cells with donor-derived enzyme-competent cells in vascular and extravascular compartments of the body [
         <a href="#rid38">
          38
         </a>
         ]. HCT has been used most successfully to treat Hurler syndrome (MPS IH) and is routinely offered only to patients with Hurler syndrome under approximately two years of age. In this situation, HCT is considered standard of care. The risks of the procedure are considerably reduced compared with previous years, and long-term engrafted survival rates of greater than 90 percent are expected in expert institutions. The procedure-related risk is considered acceptable compared with the disease-related risk. HCT is less commonly used in milder MPS I and II and MPS VI and VII and is not considered as standard of care in the same way it is in the younger child with Hurler syndrome (
         <a class="graphic graphic_table graphicRef57733" href="/z/d/graphic/57733.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid39">
          39,40
         </a>
         ].
        </p>
        <p>
         In the majority of patients with successful engraftment, HCT reduces hepatosplenomegaly, increases joint mobility, decreases airway obstruction, improves cardiac function, decreases cerebrospinal fluid (CSF) pressure, improves or stabilizes hearing, and, especially in younger patients, may stabilize mental regression [
         <a href="#rid39">
          39,41-49
         </a>
         ]. In Hurler syndrome, HCT is more effective at preventing disease progression than reversing established disease. Clinical outcomes after transplant are most clearly related to the age at transplant (the younger the better) and to the enzyme delivered to host tissue by engrafted donor white cells. This delivered dose is better when the donor is fully rather than partially engrafted and when the donor is not a carrier of the disease [
         <a href="#rid39">
          39,41-47,50
         </a>
         ]. Enzyme replacement therapy (ERT;
         <a class="drug drug_pediatric" data-topicid="13320" href="/z/d/drug information/13320.html" rel="external">
          laronidase
         </a>
         ) is used in many transplantation centers to stabilize or improve the clinical status of patients with MPS I before and a short time after HCT.
        </p>
        <p>
         The donor cell sources for HCT include bone marrow, mobilized peripheral blood stem cells, or umbilical cord blood, and the donor may be a human leukocyte antigen (HLA) matched family donor or an HLA-matched, unrelated donor. Regardless of cell source or donor relationship, conditioning therapy (usually chemotherapy drugs) is given to the recipient to ablate the host bone marrow and host immune system. This is done so that donor hematopoietic stem cells (HSCs) are not rejected and there is a physical host marrow space into which those HSCs can engraft.
        </p>
        <p>
         HCT has been performed in more than 600 patients with Hurler syndrome [
         <a href="#rid48">
          48,50,51
         </a>
         ]. Results have improved greatly in series from both single institutions and from registry studies. In one series of 285 patients with Hurler syndrome, event-free survival at five years was 81 percent after transplantation with an HLA-matched sibling donor or a six-out-of-six matched, unrelated, cord blood donor [
         <a href="#rid50">
          50
         </a>
         ]. Results were slightly lower for those who had a 5-out-of-6 matched cord blood donor or a 10-out-of-10 HLA-matched, unrelated donor (68 and 66 percent, respectively). Survival was significantly lower in those with a four-out-of-six matched, unrelated cord blood donor or an HLA-mismatched, unrelated donor (57 and 41 percent, respectively). In another series, survival when transplanted from 2004 onward was 84 and 81 percent at one and eight years, respectively [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p>
         Engraftment is reduced when
         <a class="drug drug_pediatric" data-topicid="13103" href="/z/d/drug information/13103.html" rel="external">
          busulfan
         </a>
         is not used in the conditioning regimen or when busulfan is used but the drug is not pharmacokinetically monitored and adjusted in order to achieve a target level. In addition, ex vivo graft manipulation with T cell-depleting antibodies further reduces engraftment of donor cells [
         <a href="#rid52">
          52
         </a>
         ]. A second transplant is indicated when engraftment fails and is usually successful. There is evidence that engraftment levels are higher after cord blood transplant compared with bone marrow transplant [
         <a href="#rid50">
          50
         </a>
         ]. An additional factor in favor of cord blood as a donor cell source is that cord blood is cryopreserved and therefore immediately available, leading to a reduced interval between diagnosis and transplant.
        </p>
        <p>
         A large, multi-institutional study examined the factors that determined the long-term outcomes of different organ systems after successful HCT [
         <a href="#rid53">
          53
         </a>
         ]. Age at HCT and the intelligence quotient (IQ) at HCT were the strongest predictors of neurodevelopmental outcome. Use of radiotherapy in conditioning therapy adversely impacted subsequent neurodevelopment. A normal enzyme level after HCT was another significant predictor of superior outcome after HCT for most other organ systems including orthopedic. The course of corneal clouding is variable. Most patients have mild residual corneal clouding, but corneal transplantation is rarely required [
         <a href="#rid48">
          48
         </a>
         ]. Retinal function may decline [
         <a href="#rid54">
          54
         </a>
         ]. HCT has the least effect on the skeleton, presumably because of poor penetration of the skeletal tissues by the enzyme derived from the transplanted leukocytes. Orthopedic surgical procedures are often required, although those with a normal enzyme level grow better and require fewer interventions such as for cord compression [
         <a href="#rid39">
          39,49,55-57
         </a>
         ].
        </p>
        <p>
         In patients with Hurler syndrome and cardiomyopathy, ERT before HCT may be lifesaving [
         <a href="#rid58">
          58-60
         </a>
         ]. In one series of 18 patients in whom
         <a class="drug drug_pediatric" data-topicid="13320" href="/z/d/drug information/13320.html" rel="external">
          laronidase
         </a>
         was continued until donor cell engraftment, the survival and engraftment rate was 89 percent [
         <a href="#rid60">
          60
         </a>
         ]. The use of laronidase was not associated with increased risk of graft-versus-host disease (GVHD) or graft failure. The use of ERT before HCT and until donor engraftment in patients with Hurler syndrome is also associated with improved cognitive outcomes [
         <a href="#rid61">
          61
         </a>
         ]. (See
         <a class="local">
          'MPS I'
         </a>
         above.)
        </p>
        <p>
         HCT has also improved the clinical outcomes of patients with milder MPS I and II and MPS VI and VII [
         <a href="#rid62">
          62-66
         </a>
         ]. However, HCT has not prevented the central nervous system (CNS) decline in patients with severe MPS II in most series and has not been successful in other types of MPS [
         <a href="#rid39">
          39
         </a>
         ]. MPS III A to D patients usually do not benefit and may worsen after the procedure [
         <a href="#rid67">
          67,68
         </a>
         ]. HCT does not correct well the bony abnormalities in MPS IV A and IV B or MPS I. The reason for the lack of success of HCT in some types of MPS is uncertain, although it is possible that the transplanted cells do not secrete sufficient enzyme or the enzyme may not be taken up sufficiently to correct the deficiency. It is possible that outcomes in some of these populations may improve with early HCT with full donor engraftment from a noncarrier donor. This question warrants further study.
        </p>
        <p class="headingAnchor" id="H1909184740">
         <span class="h1">
          GENE THERAPY AND GENE EDITING
         </span>
         <span class="headingEndMark">
          —
         </span>
         Human gene therapy studies have begun in MPS VI and are slated to take place in the next few years in MPS IIIA, IIIB, II, and IH [
         <a href="#rid69">
          69
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/98724.html" rel="external">
          "Overview of gene therapy, gene editing, and gene silencing"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H46036059">
         <span class="h2">
          Rationale
         </span>
         <span class="headingEndMark">
          —
         </span>
         The rationale for gene therapy in MPS stems from the observation in patients who have undergone hematopoietic cell transplantation (HCT) for Hurler syndrome (MPS IH) that clinical outcome is improved when engraftment is complete and a noncarrier donor was used compared with incomplete engraftment or use of a carrier donor. In addition, enzyme replacement therapy (ERT) is costly, requires lifelong infusions, and has limited efficacy on skeletal, cardiac, pulmonary, and ophthalmologic complications. Gene therapy has been associated with some benefits in murine models of MPS, and it has been shown to be more effective than conventional HCT in non-MPS lysosomal storage diseases including metachromatic leukodystrophy [
         <a href="#rid70">
          70-72
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6195.html" rel="external">
          "Metachromatic leukodystrophy", section on 'Treatment'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3787056841">
         <span class="h2">
          Stem cell gene therapy using viral vectors
         </span>
         <span class="headingEndMark">
          —
         </span>
         In stem cell gene therapy approaches, autologous hematopoietic stem cells (HSCs) are transduced with an adenovirus or lentivirus vector that delivers healthy gene copies with a promoter that ensures gene expression in the progeny of the corrected stem cell. In this way, all patients have a well-matched donor, and immune suppression is not required after transplant.
        </p>
        <p>
         In a phase-I/II open-label study of gene therapy for MPS VI, nine patients over four years of age were sequentially enrolled to receive one of three doses (low, intermediate, and high) of an adenovirus vector expressing arylsulfatase B (ARSB) [
         <a href="#rid73">
          73
         </a>
         ]. Patients in the high-dose group had levels of serum ARSB that were 30 to 100 percent of the mean normal level and were sustained over the two-year study period. Urinary glycosaminoglycans (GAG), metabolites that accumulates in untreated MPS VI and are excreted in the urine, were only modestly increased in the high-dose group. No clinical deterioration was noted in this group, and resumption of ERT was not required. Low- and intermediate-dose gene therapy was less efficacious, with serum ARSB levels only 20 percent of the mean normal level and urinary GAG levels sufficiently high that patients were required to restart ERT. No serious adverse events attributable to therapy were reported.
        </p>
        <p class="headingAnchor" id="H2783750927">
         <span class="h2">
          Gene editing
         </span>
         <span class="headingEndMark">
          —
         </span>
         The
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2Fstudy%2FNCT02702115&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSye0MVTszSOnCQ2xstv1FTzFIenJZYWqQn4BkmuJjmEaw%3D%3D&amp;TOPIC_ID=113802" target="_blank">
          EMPOWERS
         </a>
         clinical research study is enrolling adults with MPS I
         <strong>
         </strong>
         to test an investigational type of gene therapy called genome or gene editing (by the zinc finger nuclease) as a potentially lasting treatment. The goal of this treatment is to permanently produce enough of the missing enzyme to reduce or abrogate symptoms and prevent complications.
        </p>
        <p class="headingAnchor" id="H3317517005">
         <span class="h1">
          OTHER THERAPIES
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_pediatric" data-topicid="109479" href="/z/d/drug information/109479.html" rel="external">
          Miglustat
         </a>
         , an inhibitor of glucosylceramide synthase that crosses the blood-brain barrier, did not improve or stabilize behavior or decrease ganglioside levels in a randomized trial of 25 patients with MPS III [
         <a href="#rid74">
          74
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2089874312">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/120240.html" rel="external">
          "Society guideline links: Mucopolysaccharidoses"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H332262590">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical features
         </strong>
         – The mucopolysaccharidoses (MPS) are lysosomal storage disorders that are differentiated by their clinical features and age of presentation (
         <a class="graphic graphic_table graphicRef57733" href="/z/d/graphic/57733.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/2931.html" rel="external">
          "Mucopolysaccharidoses: Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Overview of management
         </strong>
         – Most therapies for MPS are directed toward treatment of complications and are not specific for the underlying abnormality. Supportive or symptomatic management can improve the quality of life for patients and their families but cannot prevent the inevitable decline in function. (See
         <a class="local">
          'Overview of management'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/2932.html" rel="external">
          "Mucopolysaccharidoses: Complications"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Specific therapies
         </strong>
         – Specific therapies, such as enzyme replacement or hematopoietic cell transplantation (ERT or HCT), may alter the natural history of these disorders. The choice of therapy depends upon the type of MPS and the disease severity in the specific patient. (See
         <a class="local">
          'Overview of management'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Enzyme replacement therapy
         </strong>
         – Therapy to replace the defective enzyme is available for MPS I, II, IVA, VI, and VII. Indications vary across the MPS, but generally ERT is used in patients with moderate-to-severe disease or clinical complications. (See
         <a class="local">
          'Enzyme replacement therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Hematopoietic cell transplantation
         </strong>
         – HCT is the standard of care for patients less than two years of age with Hurler syndrome (a severe form of MPS I). It is less commonly used in milder MPS I and II and MPS VI and VII. (See
         <a class="local">
          'Hematopoietic cell transplantation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Gene therapy/editing
         </strong>
         – Gene therapy and gene editing for MPS is an active area of exploration. (See
         <a class="local">
          'Gene therapy and gene editing'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3540534899">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Ed Wraith, MD; Emil Kakkis, MD, PhD; Robert Wynn, MD, MRCP, FRCPath; and Simon Jones, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Safary A, Moghaddas-Sani H, Akbarzadeh-Khiavi M, et al. Enzyme replacement combinational therapy: effective treatments for mucopolysaccharidoses. Expert Opin Biol Ther 2021; 21:1181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dietz HC. New therapeutic approaches to mendelian disorders. N Engl J Med 2010; 363:852.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kakkis ED, Muenzer J, Tiller GE, et al. Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med 2001; 344:182.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wraith JE, Clarke LA, Beck M, et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). J Pediatr 2004; 144:581.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sifuentes M, Doroshow R, Hoft R, et al. A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years. Mol Genet Metab 2007; 90:171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laraway S, Mercer J, Jameson E, et al. Outcomes of Long-Term Treatment with Laronidase in Patients with Mucopolysaccharidosis Type I. J Pediatr 2016; 178:219.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jameson E, Jones S, Remmington T. Enzyme replacement therapy with laronidase (Aldurazyme®) for treating mucopolysaccharidosis type I. Cochrane Database Syst Rev 2019; 6:CD009354.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gabrielli O, Clarke LA, Bruni S, Coppa GV. Enzyme-replacement therapy in a 5-month-old boy with attenuated presymptomatic MPS I: 5-year follow-up. Pediatrics 2010; 125:e183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clarke LA, Wraith JE, Beck M, et al. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics 2009; 123:229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kakavanos R, Turner CT, Hopwood JJ, et al. Immune tolerance after long-term enzyme-replacement therapy among patients who have mucopolysaccharidosis I. Lancet 2003; 361:1608.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wraith JE, Beck M, Lane R, et al. Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L-iduronidase (laronidase). Pediatrics 2007; 120:e37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pitz S, Ogun O, Bajbouj M, et al. Ocular changes in patients with mucopolysaccharidosis I receiving enzyme replacement therapy: a 4-year experience. Arch Ophthalmol 2007; 125:1353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dickson P, McEntee M, Vogler C, et al. Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid. Mol Genet Metab 2007; 91:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nestrasil I, Shapiro E, Svatkova A, et al. Intrathecal enzyme replacement therapy reverses cognitive decline in mucopolysaccharidosis type I. Am J Med Genet A 2017; 173:780.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Munoz-Rojas MV, Vieira T, Costa R, et al. Intrathecal enzyme replacement therapy in a patient with mucopolysaccharidosis type I and symptomatic spinal cord compression. Am J Med Genet A 2008; 146A:2538.
          </a>
         </li>
         <li class="breakAll">
          FDA News. FDA approves first treatment for Hunter syndrome. July 24, 2006. www.fda.gov/bbs/topics/NEWS/2006/NEW01418.html (Accessed on August 01, 2006).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muenzer J, Martins AM. Hunter syndrome: to treat or not to treat. Acta Paediatr 2008; 97:55.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           da Silva EM, Strufaldi MW, Andriolo RB, Silva LA. Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome). Cochrane Database Syst Rev 2016; 2:CD008185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wraith JE, Scarpa M, Beck M, et al. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr 2008; 167:267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wikman-Jorgensen PE, López Amorós A, Peris García J, et al. Enzyme replacement therapy for the treatment of Hunter disease: A systematic review with narrative synthesis and meta-analysis. Mol Genet Metab 2020; 131:206.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muenzer J, Bodamer O, Burton B, et al. The role of enzyme replacement therapy in severe Hunter syndrome-an expert panel consensus. Eur J Pediatr 2012; 171:181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muenzer J, Wraith JE, Beck M, et al. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med 2006; 8:465.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lampe C, Bosserhoff AK, Burton BK, et al. Long-term experience with enzyme replacement therapy (ERT) in MPS II patients with a severe phenotype: an international case series. J Inherit Metab Dis 2014; 37:823.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muenzer J, Beck M, Giugliani R, et al. Idursulfase treatment of Hunter syndrome in children younger than 6 years: results from the Hunter Outcome Survey. Genet Med 2011; 13:102.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tylki-Szymanska A, Jurecka A, Zuber Z, et al. Enzyme replacement therapy for mucopolysaccharidosis II from 3 months of age: a 3-year follow-up. Acta Paediatr 2012; 101:e42.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jones SA, Breen C, Heap F, et al. A phase 1/2 study of intrathecal heparan-N-sulfatase in patients with mucopolysaccharidosis IIIA. Mol Genet Metab 2016; 118:198.
          </a>
         </li>
         <li class="breakAll">
          FDA News Release: FDA approves Vimizim to treat rare congenital enzyme disorder. http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm386008.htm.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hendriksz CJ, Burton B, Fleming TR, et al. Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study. J Inherit Metab Dis 2014; 37:979.
          </a>
         </li>
         <li class="breakAll">
          U.S. Food and Drug Administration. Center for Drug Evaluation and Research. www.accessdata.fda.gov/scripts/cder/drugsatfda (Accessed on September 26, 2006).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harmatz P, Whitley CB, Waber L, et al. Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). J Pediatr 2004; 144:574.
          </a>
         </li>
         <li class="breakAll">
          Naglazyme (galsulfase) product label. Biomarin Pharmaceutical Inc, Novato, CA.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harmatz P, Ketteridge D, Giugliani R, et al. Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase. Pediatrics 2005; 115:e681.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harmatz P, Giugliani R, Schwartz I, et al. Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J Pediatr 2006; 148:533.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brunelli MJ, Atallah ÁN, da Silva EM. Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI. Cochrane Database Syst Rev 2016; 3:CD009806.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giugliani R, Lampe C, Guffon N, et al. Natural history and galsulfase treatment in mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome)--10-year follow-up of patients who previously participated in an MPS VI Survey Study. Am J Med Genet A 2014; 164A:1953.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Auclair D, Finnie J, White J, et al. Repeated intrathecal injections of recombinant human 4-sulphatase remove dural storage in mature mucopolysaccharidosis VI cats primed with a short-course tolerisation regimen. Mol Genet Metab 2010; 99:132.
          </a>
         </li>
         <li class="breakAll">
          First FDA approved treatment for pediatric and adult patients with MPS VII. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm585308.htm.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krivit W, Sung JH, Shapiro EG, Lockman LA. Microglia: the effector cell for reconstitution of the central nervous system following bone marrow transplantation for lysosomal and peroxisomal storage diseases. Cell Transplant 1995; 4:385.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prasad VK, Kurtzberg J. Transplant outcomes in mucopolysaccharidoses. Semin Hematol 2010; 47:59.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Montaño AM, Lock-Hock N, Steiner RD, et al. Clinical course of sly syndrome (mucopolysaccharidosis type VII). J Med Genet 2016; 53:403.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peters C, Shapiro EG, Anderson J, et al. Hurler syndrome: II. Outcome of HLA-genotypically identical sibling and HLA-haploidentical related donor bone marrow transplantation in fifty-four children. The Storage Disease Collaborative Study Group. Blood 1998; 91:2601.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guffon N, Souillet G, Maire I, et al. Follow-up of nine patients with Hurler syndrome after bone marrow transplantation. J Pediatr 1998; 133:119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vellodi A, Young EP, Cooper A, et al. Bone marrow transplantation for mucopolysaccharidosis type I: experience of two British centres. Arch Dis Child 1997; 76:92.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peters C, Balthazor M, Shapiro EG, et al. Outcome of unrelated donor bone marrow transplantation in 40 children with Hurler syndrome. Blood 1996; 87:4894.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Whitley CB, Belani KG, Chang PN, et al. Long-term outcome of Hurler syndrome following bone marrow transplantation. Am J Med Genet 1993; 46:209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hopwood JJ, Vellodi A, Scott HS, et al. Long-term clinical progress in bone marrow transplanted mucopolysaccharidosis type I patients with a defined genotype. J Inherit Metab Dis 1993; 16:1024.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malm G, Gustafsson B, Berglund G, et al. Outcome in six children with mucopolysaccharidosis type IH, Hurler syndrome, after haematopoietic stem cell transplantation (HSCT). Acta Paediatr 2008; 97:1108.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aldenhoven M, Boelens JJ, de Koning TJ. The clinical outcome of Hurler syndrome after stem cell transplantation. Biol Blood Marrow Transplant 2008; 14:485.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grigull L, Sykora KW, Tenger A, et al. Variable disease progression after successful stem cell transplantation: prospective follow-up investigations in eight patients with Hurler syndrome. Pediatr Transplant 2011; 15:861.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boelens JJ, Aldenhoven M, Purtill D, et al. Outcomes of transplantation using various hematopoietic cell sources in children with Hurler syndrome after myeloablative conditioning. Blood 2013; 121:3981.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodgers NJ, Kaizer AM, Miller WP, et al. Mortality after hematopoietic stem cell transplantation for severe mucopolysaccharidosis type I: the 30-year University of Minnesota experience. J Inherit Metab Dis 2017; 40:271.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boelens JJ, Wynn RF, O'Meara A, et al. Outcomes of hematopoietic stem cell transplantation for Hurler's syndrome in Europe: a risk factor analysis for graft failure. Bone Marrow Transplant 2007; 40:225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aldenhoven M, Wynn RF, Orchard PJ, et al. Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study. Blood 2015; 125:2164.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gullingsrud EO, Krivit W, Summers CG. Ocular abnormalities in the mucopolysaccharidoses after bone marrow transplantation. Longer follow-up. Ophthalmology 1998; 105:1099.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tandon V, Williamson JB, Cowie RA, Wraith JE. Spinal problems in mucopolysaccharidosis I (Hurler syndrome). J Bone Joint Surg Br 1996; 78:938.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Field RE, Buchanan JA, Copplemans MG, Aichroth PM. Bone-marrow transplantation in Hurler's syndrome. Effect on skeletal development. J Bone Joint Surg Br 1994; 76:975.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Masterson EL, Murphy PG, O'Meara A, et al. Hip dysplasia in Hurler's syndrome: orthopaedic management after bone marrow transplantation. J Pediatr Orthop 1996; 16:731.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hirth A, Berg A, Greve G. Successful treatment of severe heart failure in an infant with Hurler syndrome. J Inherit Metab Dis 2007; 30:820.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cox-Brinkman J, Boelens JJ, Wraith JE, et al. Haematopoietic cell transplantation (HCT) in combination with enzyme replacement therapy (ERT) in patients with Hurler syndrome. Bone Marrow Transplant 2006; 38:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wynn RF, Mercer J, Page J, et al. Use of enzyme replacement therapy (Laronidase) before hematopoietic stem cell transplantation for mucopolysaccharidosis I: experience in 18 patients. J Pediatr 2009; 154:135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eisengart JB, Rudser KD, Tolar J, et al. Enzyme replacement is associated with better cognitive outcomes after transplant in Hurler syndrome. J Pediatr 2013; 162:375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vellodi A, Young E, Cooper A, et al. Long-term follow-up following bone marrow transplantation for Hunter disease. J Inherit Metab Dis 1999; 22:638.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McKinnis EJ, Sulzbacher S, Rutledge JC, et al. Bone marrow transplantation in Hunter syndrome. J Pediatr 1996; 129:145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krivit W. Maroteaux-Lamy syndrome (mucopolysaccharidosis VI): Treatment by allogeneic bone marrow transplantation in 6 patients and potential for autotransplantation bone marrow gene insertion. Int Pediatr 1992; 7:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamada Y, Kato K, Sukegawa K, et al. Treatment of MPS VII (Sly disease) by allogeneic BMT in a female with homozygous A619V mutation. Bone Marrow Transplant 1998; 21:629.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guffon N, Bertrand Y, Forest I, et al. Bone marrow transplantation in children with Hunter syndrome: outcome after 7 to 17 years. J Pediatr 2009; 154:733.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shapiro EG, Lockman LA, Balthazor M, Krivit W. Neuropsychological outcomes of several storage diseases with and without bone marrow transplantation. J Inherit Metab Dis 1995; 18:413.
          </a>
         </li>
         <li class="breakAll">
          Krivit W, Whitley CB, Chang P, et al. Lysosomal storage diseases treated by bone marrow transplantation: Review of 21 patients. In: Bone marrow transplantation in children, Johnson E, Pochedly C (Eds), Raven Press, New York 1990. p.261.
         </li>
         <li>
          <a class="nounderline abstract_t">
           McBride KL, Flanigan KM. Update in the Mucopolysaccharidoses. Semin Pediatr Neurol 2021; 37:100874.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fraldi A, Serafini M, Sorrentino NC, et al. Gene therapy for mucopolysaccharidoses: in vivo and ex vivo approaches. Ital J Pediatr 2018; 44:130.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holley RJ, Wood SR, Bigger BW. Delivering Hematopoietic Stem Cell Gene Therapy Treatments for Neurological Lysosomal Diseases. ACS Chem Neurosci 2019; 10:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sawamoto K, Chen HH, Alméciga-Díaz CJ, et al. Gene therapy for Mucopolysaccharidoses. Mol Genet Metab 2018; 123:59.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brunetti-Pierri N, Ferla R, Ginocchio VM, et al. Liver-directed adeno-associated virus–mediated gene therapy for mucopolysaccharidosis type VI. NEJM Evid 2022; 1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guffon N, Bin-Dorel S, Decullier E, et al. Evaluation of miglustat treatment in patients with type III mucopolysaccharidosis: a randomized, double-blind, placebo-controlled study. J Pediatr 2011; 159:838.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 113802 Version 10.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33653197" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Enzyme replacement combinational therapy: effective treatments for mucopolysaccharidoses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20818846" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : New therapeutic approaches to mendelian disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11172140" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Enzyme-replacement therapy in mucopolysaccharidosis I.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15126990" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17011223" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27788836" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Outcomes of Long-Term Treatment with Laronidase in Patients with Mucopolysaccharidosis Type I.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31211405" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Enzyme replacement therapy with laronidase (Aldurazyme®) for treating mucopolysaccharidosis type I.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20026495" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Enzyme-replacement therapy in a 5-month-old boy with attenuated presymptomatic MPS I: 5-year follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19117887" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12747881" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Immune tolerance after long-term enzyme-replacement therapy among patients who have mucopolysaccharidosis I.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17606547" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L-iduronidase (laronidase).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17923542" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Ocular changes in patients with mucopolysaccharidosis I receiving enzyme replacement therapy: a 4-year experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17321776" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28211988" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Intrathecal enzyme replacement therapy reverses cognitive decline in mucopolysaccharidosis type I.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18792977" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Intrathecal enzyme replacement therapy in a patient with mucopolysaccharidosis type I and symptomatic spinal cord compression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18792977" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Intrathecal enzyme replacement therapy in a patient with mucopolysaccharidosis type I and symptomatic spinal cord compression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18339189" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Hunter syndrome: to treat or not to treat.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26845288" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18038146" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32773276" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Enzyme replacement therapy for the treatment of Hunter disease: A systematic review with narrative synthesis and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22037758" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : The role of enzyme replacement therapy in severe Hunter syndrome-an expert panel consensus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16912578" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24596019" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Long-term experience with enzyme replacement therapy (ERT) in MPS II patients with a severe phenotype: an international case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21233716" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Idursulfase treatment of Hunter syndrome in children younger than 6 years: results from the Hunter Outcome Survey.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21672014" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Enzyme replacement therapy for mucopolysaccharidosis II from 3 months of age: a 3-year follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27211612" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : A phase 1/2 study of intrathecal heparan-N-sulfatase in patients with mucopolysaccharidosis IIIA.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27211612" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : A phase 1/2 study of intrathecal heparan-N-sulfatase in patients with mucopolysaccharidosis IIIA.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24810369" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24810369" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15126989" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15126989" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15930196" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16647419" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26943923" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24764221" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Natural history and galsulfase treatment in mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome)--10-year follow-up of patients who previously participated in an MPS VI Survey Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19896877" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Repeated intrathecal injections of recombinant human 4-sulphatase remove dural storage in mature mucopolysaccharidosis VI cats primed with a short-course tolerisation regimen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19896877" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Repeated intrathecal injections of recombinant human 4-sulphatase remove dural storage in mature mucopolysaccharidosis VI cats primed with a short-course tolerisation regimen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7582569" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Microglia: the effector cell for reconstitution of the central nervous system following bone marrow transplantation for lysosomal and peroxisomal storage diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20109613" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Transplant outcomes in mucopolysaccharidoses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26908836" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Clinical course of sly syndrome (mucopolysaccharidosis type VII).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9516162" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Hurler syndrome: II. Outcome of HLA-genotypically identical sibling and HLA-haploidentical related donor bone marrow transplantation in fifty-four children. The Storage Disease Collaborative Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9672523" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Follow-up of nine patients with Hurler syndrome after bone marrow transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9068295" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Bone marrow transplantation for mucopolysaccharidosis type I: experience of two British centres.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8639864" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Outcome of unrelated donor bone marrow transplantation in 40 children with Hurler syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8484412" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Long-term outcome of Hurler syndrome following bone marrow transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8127052" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Long-term clinical progress in bone marrow transplanted mucopolysaccharidosis type I patients with a defined genotype.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18452566" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Outcome in six children with mucopolysaccharidosis type IH, Hurler syndrome, after haematopoietic stem cell transplantation (HSCT).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18410891" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : The clinical outcome of Hurler syndrome after stem cell transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22112002" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Variable disease progression after successful stem cell transplantation: prospective follow-up investigations in eight patients with Hurler syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23493783" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Outcomes of transplantation using various hematopoietic cell sources in children with Hurler syndrome after myeloablative conditioning.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28054207" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Mortality after hematopoietic stem cell transplantation for severe mucopolysaccharidosis type I: the 30-year University of Minnesota experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17529997" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Outcomes of hematopoietic stem cell transplantation for Hurler's syndrome in Europe: a risk factor analysis for graft failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25624320" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9627663" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Ocular abnormalities in the mucopolysaccharidoses after bone marrow transplantation. Longer follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8951011" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Spinal problems in mucopolysaccharidosis I (Hurler syndrome).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7983131" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Bone-marrow transplantation in Hurler's syndrome. Effect on skeletal development.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8906643" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Hip dysplasia in Hurler's syndrome: orthopaedic management after bone marrow transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17768668" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Successful treatment of severe heart failure in an infant with Hurler syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16715104" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Haematopoietic cell transplantation (HCT) in combination with enzyme replacement therapy (ERT) in patients with Hurler syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19187736" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Use of enzyme replacement therapy (Laronidase) before hematopoietic stem cell transplantation for mucopolysaccharidosis I: experience in 18 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22974573" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Enzyme replacement is associated with better cognitive outcomes after transplant in Hurler syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10399096" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Long-term follow-up following bone marrow transplantation for Hunter disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8757575" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Bone marrow transplantation in Hunter syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Maroteaux-Lamy syndrome (mucopolysaccharidosis VI): Treatment by allogeneic bone marrow transplantation in 6 patients and potential for autotransplantation bone marrow gene insertion
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9543069" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Treatment of MPS VII (Sly disease) by allogeneic BMT in a female with homozygous A619V mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19167723" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Bone marrow transplantation in children with Hunter syndrome: outcome after 7 to 17 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7494400" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Neuropsychological outcomes of several storage diseases with and without bone marrow transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7494400" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Neuropsychological outcomes of several storage diseases with and without bone marrow transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33892850" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Update in the Mucopolysaccharidoses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30442177" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Gene therapy for mucopolysaccharidoses: in vivo and ex vivo approaches.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30136572" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Delivering Hematopoietic Stem Cell Gene Therapy Treatments for Neurological Lysosomal Diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29295764" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Gene therapy for Mucopolysaccharidoses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Liver-directed adeno-associated virus–mediated gene therapy for mucopolysaccharidosis type VI
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21658716" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Evaluation of miglustat treatment in patients with type III mucopolysaccharidosis: a randomized, double-blind, placebo-controlled study.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
